<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00866203</url>
  </required_header>
  <id_info>
    <org_study_id>LA05</org_study_id>
    <nct_id>NCT00866203</nct_id>
  </id_info>
  <brief_title>HDS Plus PBPC Transplant Vs 4 More Courses of FrontLine Therapy in Pts With Aggressive NHL in PR After Induction Therapy</brief_title>
  <official_title>A Prospective, Randomized, Multicenter Trial Comparing a Modified HDS Therapy Supported by PBPC Transplant With Additional 4 Courses of Front-Line Therapy in Adult Aggressive NHL With PR After Short Course of Up-Front Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Studio Linfomi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Studio Linfomi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is planned to compare the outcome of aggressive NHL patients in partial remission
      after four courses of front-line therapy, randomly assigned to receive either additional four
      courses of the same regimen or a modified HDS program.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2000</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>remission duration</measure>
    <time_frame>end of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>study end</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>event-free survival</measure>
    <time_frame>study end</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>freedom-from progression</measure>
    <time_frame>study end</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>feasibility and toxicity</measure>
    <time_frame>end of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">441</enrollment>
  <condition>High-Grade Lymphomas</condition>
  <arm_group>
    <arm_group_label>HDS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>modified high dose sequential therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ProMECE/CytaBOM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>four additional courses of standard ProMECE/CytaBOM</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HDS vs ProMECE/CytaBOM</intervention_name>
    <arm_group_label>HDS</arm_group_label>
    <arm_group_label>ProMECE/CytaBOM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed, untreated patients with histologically documented aggressive
             lymphoma;

          -  Age between 18 and 65 years;

          -  Clinical stage at diagnosis: I A bulky - IV B;

          -  Reduction of tumoral masses, after four courses of induction therapy, between 50 and
             75%;

          -  Serum negativity for HIV, HbsAg and HCV;

          -  ECOG performance status 0 through 4;

          -  Adequate bone marrow function;

          -  Adequate renal and hepatic functions;

          -  Left ventricular ejection fraction (LVEF) &gt; 50%;

          -  No previous malignant disease;

          -  No previous chemo-radiotherapy;

          -  No cerebral or CNS involvement, assessed by clinical history, physical examination and
             CSF examination through lumbar puncture;

          -  Written informed consent given at time of randomization.

        Exclusion Criteria:

          -  Clinical stage I no bulky, or CS IIA-B with less than three sites of disease involved;

          -  Patients with CR, unconfirmed complete remission (uCR), very good PR (&gt;75%) and
             clinical response less than 50%, as defined by Cheson et al., following four courses
             of induction therapy;

          -  Tumor involvement of CNS (except patients with peridural masses without liquor
             involvement , who can be enrolled in this study);

          -  Indolent lymphoma transformed in more aggressive histologic type, even if never
             previously treated;

          -  Aggressive non-Hodgkin's lymphoma in pre-transplanted patient;

          -  Clinically significant secondary cardiovascular disease e.g. uncontrolled
             hypertension, (resting diastolic blood pressure &gt; 115 mmHg), uncontrolled multifocal
             cardiac arrhythmias, symptomatic angina pectoris or congestive cardiac failure NYHA
             class III-IV;

          -  Left ventricular ejection fraction (LVEF) &lt; 50%;

          -  Evidence of any severe active acute or chronic infection;

          -  Concurrent malignancy of history of other malignancy, except basal cell carcinoma of
             the skin (BCC) and in situ cervical carcinoma (CIN);

          -  myelodisplastic syndrome;

          -  HbsAg, HIV-positive, or HCV-RNA-positive patients;

          -  Patient with psychiatric, or any disorder that compromises ability to give truly
             informed consent for participation in this study;

          -  Pregnant woman; potential child-bearing women can be enrolled if adequate
             contraceptive precautions are used before entering this trial and for the duration of
             the trial;

          -  Concerns for patient's compliance with the protocol procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicola Di Renzo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>GISL</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Massimo Federico, MD</last_name>
    <role>Study Chair</role>
    <affiliation>GISL</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maura Brugiatelli, MD</last_name>
    <role>Study Chair</role>
    <affiliation>GISL</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mario Petrini, MD</last_name>
    <role>Study Chair</role>
    <affiliation>GISL</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paolo G Gobbi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>GISL</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GISL Trial Office</name>
      <address>
        <city>Modena</city>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2007</study_first_submitted>
  <study_first_submitted_qc>March 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2009</study_first_posted>
  <last_update_submitted>March 19, 2009</last_update_submitted>
  <last_update_submitted_qc>March 19, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2009</last_update_posted>
  <responsible_party>
    <name_title>sponsor</name_title>
    <organization>Gruppo Italiano Studio Linfomi</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

